Document is current

Article History

Accepted: 7 August 2024

First Online: 16 September 2024

Declarations

:

: Aysenur Yaliniz, Mathieu Blouin, Marie-Élaine Métras, Marie-Christine Boulanger, Karine Cloutier, Marie-Hélène Dubé, Julie Autmizguine and Amélie Marsot declare no conflict of interest.

: All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The study was approved by the academic ethic committee of Université de Montréal on March 2, 2021 (CERC-21-033-R). The multicentric research protocol was previously approved (MP-21-2021-3329) by the Centre Hospitalier Universitaire Sainte-Justine’s ethics committees on June 8, 2022 and certified via an institutional feasibility review (MEO-21-2023-6385) by the Centre Mère-Enfant-Soleil du CHU de Québec-Université Laval. Preliminary results were presented at five scientific meetings from December 2022 to January 2024. Four of these meetings were held locally in Quebec, Canada, while one took place internationally in Oslo, Norway. The latter was the 21st edition of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology’s congress and the presentation was titled: Use of vancomycin population pharmacokinetic model in pediatric patients with cystic fibrosis: impact of data on the predictive performance.

: Authorization to access patient records has been obtained from the Centre Hospitalier Universitaire Sainte-Justine and Centre Mère-Enfant-Soleil du CHU de Québec-Université Laval. Since the data were collected retrospectively and anonymously, individual informed consent from the participants was not required.

: Not applicable.